1. Home
  2. STEX vs PBYI Comparison

STEX vs PBYI Comparison

Compare STEX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$2.13

Market Cap

297.8M

Sector

N/A

ML Signal

N/A

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

N/A

Current Price

$6.20

Market Cap

263.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STEX
PBYI
Founded
2009
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.8M
263.4M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
STEX
PBYI
Price
$2.13
$6.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$7.00
AVG Volume (30 Days)
2.0M
478.8K
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.61
Revenue
N/A
$27,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$9.93
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$2.58
52 Week High
$7.44
$7.68

Technical Indicators

Market Signals
Indicator
STEX
PBYI
Relative Strength Index (RSI) 38.30 44.96
Support Level $2.04 $5.57
Resistance Level $3.68 $7.25
Average True Range (ATR) 0.21 0.45
MACD 0.01 -0.12
Stochastic Oscillator 23.45 32.80

Price Performance

Historical Comparison
STEX
PBYI

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: